Magazine article from our research archive:

New formulations

Parcopa

Carbidopa-levodopa orally disintegrating tablets

SCHWARZ PHARMA

Rapid-dissolving Parkinson's tablet approved for ease of dosing

Since current evidence indicates that the symptoms of Parkinson's disease are related to a depletion of dopamine in the corpus striatum, levodopa has been chosen as a therapy because it crosses the blood-brain barrier to the brain, where it is presumably converted to dopamine. Carbidopa inhibits the decarboxylation of peripheral levodopa, which reduces the dose of levodopa necessary to produce a response in Parkinson's disease patients, thereby lessening the severity of levodopa-associated adverse events. The carbidopa-levodopa orally disintegrating tablet ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!